Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

CardiAQ Valve Technologies names CEO

California-based CardiAQ Valve Technologies (CVT), a developer of self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), has appointed Rob Michiels as chief executive officer (CEO), effective immediately.

Michiels will remain as a director of CVT.

He was president and COO at CoreValve, which was acquired by Medtronic for $700m plus milestone payments in April 2009.

Michiels has also served as CEO of VenPro, general manager/corporate officer of EndoSonics and president/COO of InterVentional Technologies.

He is a founding partner of Consilium, a medical device market research company that is also active in identifying, funding, and greenhousing start-up technologies.

Michiels said as already demonstrated on the aortic side, heart valve therapy will transition to a less-invasive protocol during the coming decade and within that new paradigm, CVT is positioned to offer a percutaneous implantation procedure for the definitive treatment of Mitral Regurgitation.

"While several companies are trying to perfect a percutaneous approach to repair the mitral valve, I feel that these will have a very difficult time demonstrating sufficient efficacy in treating a disease that is very diverse, while CVT’s non-surgical valve implantation approach could become a disruptive technology with a much broader application," Michiels said.